FDA Approval of ANZUPGO: A New Chronic Hand Eczema Treatment

The FDA has approved ANZUPGO® (delgocitinib cream), a major advancement. It is the first topical treatment for moderate-to-severe chronic hand eczema (CHE) in adults, developed by LEO Pharma. This pan-JAK inhibitor targets multiple inflammatory pathways (JAK1, JAK2, JAK3, TYK2), and represents a breakthrough for CHE, which affects about 10% of adults globally. Pivotal trials showed significant skin clearance and symptom relief compared to inert vehicles.

Key Insights

ANZUPGO’s FDA approval highlights its pan-JAK inhibition, setting it apart from selective JAK1 inhibitors like Opzelura. This broader targeting addresses CHE’s multifactorial inflammation, including Th1, Th2, and Th17 pathways. DELTA trials showed 20-29% of ANZUPGO users achieved near-clear skin at 16 weeks, versus 7-10% for placebo. As a topical agent, it reduces systemic risks linked to oral JAK inhibitors, such as cancer.

Chronic hand eczema (CHE) causes painful, cracked, or blistered hands, and occupational exposures, like in healthcare, often worsen it. Before ANZUPGO, treatments included off-label steroids or risky systemic immunosuppressants. CHE’s psychological and functional burdens are severe, while up to 70% of severe cases limit daily activities and careers.

Implications

ANZUPGO’s approval may make it the standard-of-care for CHE, reducing reliance on risky off-label therapies. Its targeted approach could improve outcomes and lower long-term costs. It may also ease productivity losses in high-impact jobs.

For more details, refer to LEO Pharma’s source article.